Expression of sigma 1 receptor in human breast cancer

Breast Cancer Research and Treatment

Volumn 87, Issue 3, 2004, Pages 205-214

  Wang, B ^a   Rouzier, R ^a   Albarracin, C T ^a   Sahin, A ^a   Wagner, P ^a   Yang, Y ^a   Smith, T L ^a   Bernstam, F Meric ^a   Marcelo, A C ^a   Hortobagyi, G N ^a   Pusztai, L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

breast cancer; haloperidol; immunohistochemistry; ligands; RT PCR; sigma 1 receptor; SKF 10.047

Indexed keywords

DOCETAXEL; DOXORUBICIN; HALOPERIDOL; LIGAND; MESSENGER RNA; N ALLYLNORMETAZOCINE; NAVELBINE; PACLITAXEL; PROGESTERONE; SIGMA 1 OPIATE RECEPTOR;

ARTICLE; BREAST CANCER; BREAST DISEASE; BREAST EPITHELIUM; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER INVASION; CARCINOMA IN SITU; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG BINDING SITE; EPITHELIUM CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA PRIMERS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTORS, SIGMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM;

EID: 8644261553     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-004-6590-0     Document Type: Article

References (23)

1. Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, Glossmann H: Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci USA 93: 8072-8077, 1996
2. Matsumoto RR, Liu Y, Lerner M, Howard EW, Brackett DJ: Sigma receptors: potential medications development target for anti-cocaine agents. Eur J Pharmacol 469: 1-12, 2003
3. Quirion R, Bowen WD, Itzhak Y, Junien JL, Musacchio JM, Rothman RB, Su TP, Tam SW, Taylor DP: A proposal for the classification of sigma binding sites. Trends Pharmacol Sci 13: 85-86, 1992
4. Monnet FP, Mahe V, Robel P, Baulieu EE: Neurosteroids, via sigma receptors, modulate the [3H]norepinephrine release evoked by N-methyl-D-aspartate in the rat hippocampus. Proc Natl Acad Sci USA 92: 3774-3778, 1995
5. Urani A, Roman FJ, Phan VL, Su TP, Maurice T: The antidepressant-like effect induced by sigma(1)-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J Pharmacol Exp Ther 298: 1269-1279, 2001
6. Seth P, Fei YJ, Li HW, Huang W, Leibach FH, Ganapathy V: Cloning and functional characterization of a sigma receptor from rat brain. J Neurochem 70: 922-931, 1998
7. Vilner BJ, John CS, Bowen WD: Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res 55: 408-413, 1995
8. Wilke RA, Mehta RP, Lupardus PJ, Chen Y, Ruoho AE, Jackson MB: Sigma receptor photolabeling and sigma receptor-mediated modulation of potassium channels in tumor cells. J Biol Chem 274: 18387-18392, 1999
9. Ela C, Barg J, Vogel Z, Hasin Y, Eilam Y: Sigma receptor ligands modulate contractility, Ca++ influx and beating rate in cultured cardiac myocytes. J Pharmacol Exp Ther 269: 1300-1309, 1994
10. Hayashi T, Maurice T, Su TP: Ca(2+) signaling via sigma(1)-receptors: novel regulatory mechanism affecting intracellular Ca(2+) concentration. J Pharmacol Exp Ther 293: 788-798, 2000
11. Brent PJ, Pang G, Little G, Dosen PJ, Van Helden DF: The sigma receptor ligand, reduced haloperidol, induces apoptosis and increases intracellular-free calcium levels [Ca2+]i in colon and mammary adenocarcinoma cells. Biochem Biophys Res Commun 219: 219-226, 1996
12. Crawford KW, Bowen WD: Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res 62: 313-322, 2002
13. Vilner BJ, Bowen WD: Sigma receptor-active neuroleptics are cytotoxic to C6 glioma cells in culture. Eur J Pharmacol 244: 199-201, 1993
14. Bowen WD: Sigma receptors: recent advances and new clinical potentials. Pharm Acta Helv 74: 211-218, 2000
15. Hellewell SB, Bruce A, Feinstein G, Orringer J, Williams W, Bowen WD: Rat liver and kidney contain high densities of sigma 1 and sigma 2 receptors: characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol 268: 9-18, 1994
16. Wolfe SA, Jr., Culp SG, De Souza EB: Sigma-receptors in endocrine organs: identification, characterization, and autoradiographic localization in rat pituitary, adrenal, testis, and ovary. Endocrinology 124: 1160-1172, 1989
17. Yang ZW, Paleos GA, Byrd JC: Expression of (+)-3-PPP binding sites in the PC12 pheochromocytoma cell line. Eur J Pharmacol 164: 607-610, 1989
18. Vilner BJ, de Costa BR, Bowen WD: Cytotoxic effects of sigma ligands: sigma receptor-mediated alterations in cellular morphology and viability. J Neurosci 15: 117-134, 1995
19. Simony-Lafontaine J, Esslimani M, Bribes E, Gourgou S, Lequeux N, Lavail R, Grenier J, Kramar A, Casellas P: Immunocytochemical assessment of sigma-1 receptor and human sterol isomerase in breast cancer and their relationship with a series of prognostic factors. Br J Cancer 82: 1958-1966, 2000
20. Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984
21. Berthois Y, Bourrie B, Galiegue S, Vidal H, Carayon P, Martin PM, Casellas P: SR31747A is a sigma receptor ligand exhibiting antitumoural activity both in vitro and in vivo. Br J Cancer 88: 438-446, 2003
22. Brent PJ, Pang GT: Sigma binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture. Eur J Pharmacol 278: 151-160, 1995
23. Moody TW, Leyton J, John C: Sigma ligands inhibit the growth of small cell lung cancer cells. Life Sci 66: 1979-1986, 2000